<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD10090000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P53779</UniProt_ID>
  <Seq_Length>464</Seq_Length>
  <Molecule_Weight>52585</Molecule_Weight>
  <KEGG_ID>hsa:5602</KEGG_ID>
  <Orthology_ID>K04440</Orthology_ID>
  <EBI_ID>EBI-713543</EBI_ID>
  <Function_Summary>Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. Plays regulatory roles in the signaling pathways during neuronal apoptosis. Phosphorylates the neuronal microtubule regulator STMN2. Acts in the regulation of the beta-amyloid precursor protein/APP signaling during neuronal differentiation by phosphorylating APP. Participates also in neurite growth in spiral ganglion neurons.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>3</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>c-Jun N-terminal kinase 3</Alias>
      <Alias>Stress-activated protein kinase JNK3</Alias>
      <Alias>MAP kinase p49 3F12</Alias>
      <Alias>SAPK1b</Alias>
      <Alias>MAPK 10</Alias>
      <Alias>MAP kinase 10</Alias>
      <Alias>Stress-activated protein kinase 1b</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the concomitant phosphorylation of threonine (T) and tyrosine (Y) residues in a Thr-Glu-Tyr (TEY) thiolester sequence in MAP kinases. It is a dual-specificity mitogen-activated protein kinase kinase and requires activation by the serine/threonine kinase, MAP kinase kinase kinase.</Detail>
      <Keyword>MAP kinase kinase activity</Keyword>
      <Ontology_ID>GO:0004708</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: JUN + ATP = JUN phosphate + ADP. This reaction is the phosphorylation and activation of members of the JUN family, a gene family that encodes nuclear transcription factors.</Detail>
      <Keyword>JUN kinase activity</Keyword>
      <Ontology_ID>GO:0004705</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription.</Detail>
      <Keyword>Regulation of transcription factor activity</Keyword>
      <Ontology_ID>GO:0051090</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>MyD88-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0002755</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 3.</Detail>
      <Keyword>Toll-like receptor 3 signaling pathway</Keyword>
      <Ontology_ID>GO:0034138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the TRIF adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>TRIF-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035666</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 1.</Detail>
      <Keyword>Toll-like receptor 1 signaling pathway</Keyword>
      <Ontology_ID>GO:0034130</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.</Detail>
      <Keyword>Toll-like receptor 4 signaling pathway</Keyword>
      <Ontology_ID>GO:0034142</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of an extracellular ligand to the Toll receptor on the surface of the target cell.</Detail>
      <Keyword>Toll signaling pathway</Keyword>
      <Ontology_ID>GO:0008063</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 2.</Detail>
      <Keyword>Toll-like receptor 2 signaling pathway</Keyword>
      <Ontology_ID>GO:0034134</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>221</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>223</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MSLHFLYYCSEPTLDVKIAFCQGFDKQVDVSYIAKHYNMSKSKVDNQFYSVEVGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAVLDRNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGEMVRHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVENRPKYAGLTFPKLFPDSLFPADSEHNKLKASQARDLLSKMLVIDPAKRISVDDALQHPYINVWYDPAEVEAPPPQIYDKQLDEREHTIEEWKELIYKEVMNSEEKTKNGVVKGQPSPSGAAVNSSESLPPSSSVNDISSMSTDQTLASDTDSSLEASAGPLGCCR</Protein_Seq>
    <DNA_Seq>AGAAATGGCGTGGCAGGGGACCCAGCGAGCCCAGAGGGATTTTGCCGCTGCTTCCTCTACCCCTGTATTTCACGCAGCTCTCTAAATTGACTCAGCTCCAGGCTAGTGTGAGAAACACCAACAGCAGGCCCATCTCAGATCTTCACTATGGCAACTTATGCAAGAAACTGTTGAATTAGACCCGTTTCCTATAGATGAGAAACCATACAAGCTGTGGTATTTATGAGCCTCCATTTCTTATACTACTGCAGTGAACCAACATTGGATGTGAAAATTGCCTTTTGTCAGGGATTCGATAAACAAGTGGATGTGTCATATATTGCCAAACATTACAACATGAGCAAAAGCAAAGTTGACAACCAGTTCTACAGTGTGGAAGTGGGAGACTCAACCTTCACAGTTCTCAAGCGCTACCAGAATCTAAAGCCTATTGGCTCTGGGGCTCAGGGCATAGTTTGTGCCGCGTATGATGCTGTCCTTGACAGAAATGTGGCCATTAAGAAGCTCAGCAGACCCTTTCAGAACCAAACACATGCCAAGAGAGCGTACCGGGAGCTGGTCCTCATGAAGTGTGTGAACCATAAAAACATTATTAGTTTATTAAATGTCTTCACACCCCAGAAAACGCTGGAGGAGTTCCAAGATGTTTACTTAGTAATGGAACTGATGGATGCCAACTTATGTCAAGTGATTCAGATGGAATTAGACCATGAGCGAATGTCTTACCTGCTGTACCAAATGTTGTGTGGCATTAAGCACCTCCATTCTGCTGGAATTATTCACAGGGATTTAAAACCAAGTAACATTGTAGTCAAGTCTGATTGCACATTGAAAATCCTGGACTTTGGACTGGCCAGGACAGCAGGCACAAGCTTCATGATGACTCCATATGTGGTGACACGTTATTACAGAGCCCCTGAGGTCATCCTGGGGATGGGCTACAAGGAGAACGTGGATATATGGTCTGTGGGATGCATTATGGGAGAAATGGTTCGCCACAAAATCCTCTTTCCAGGAAGGGACTATATTGACCAGTGGAATAAGGTAATTGAACAACTAGGAACACCATGTCCAGAATTCATGAAGAAATTGCAACCCACAGTAAGAAACTATGTGGAGAATCGGCCCAAGTATGCGGGACTCACCTTCCCCAAACTCTTCCCAGATTCCCTCTTCCCAGCGGACTCCGAGCACAATAAACTCAAAGCCAGCCAAGCCAGGGACTTGTTGTCAAAGATGCTAGTGATTGACCCAGCAAAAAGAATATCAGTGGACGACGCCTTACAGCATCCCTACATCAACGTCTGGTATGACCCAGCCGAAGTGGAGGCGCCTCCACCTCAGATATATGACAAGCAGTTGGATGAAAGAGAACACACAATTGAAGAATGGAAAGAACTTATCTACAAGGAAGTAATGAATTCAGAAGAAAAGACTAAAAATGGTGTAGTAAAAGGACAGCCTTCTCCTTCAGCACAGGTGCAGCAGTGAACAGCAGTGAGAGTCTCCCTCCATCCTCGTCTGTCAATGACATCTCCTCCATGTCCACCGACCAGACCCTGGCATCTGACACTGACAGCAGCCTGGAAGCCTCGGCAGGACCCCTGGGTTGTTGCAGGTGACTAGCCGCCTGCCTGCGAAACCCAGCGTTCTTCAGGAGATGATGTGATGGAACACACACACACGCAGACACACACACACACACAAATGCAGACACACAACATCAAGAAAACAGCAAGGGAGAGAATCCAAGCCTAAAATTAAATAAATCTTTCAGCCTGCTTCTTCCCCAGGGTTCTGTATTGCAGCTAAGCTCAAATGTATATTTAACTTCTAGTTGCTCTTGCTTTGGTCTTCTTCCAATGATGCTTACTACAGAAAGCAAATCAGACACAATTAGAGAAGCCTTTTCCATAAAGTGTAATTTTAATGGCTGCAAAACCGGCAACCTGTAACTGCCCTTTTAAATGGCATGACAAGGTGTGCAGTGGCCCCATCCAGCATGTGTGTGTCTCTATCTTGCATCTACCTGCTCCTTGGCCTAGTCAGATGGATGTAGATACAGATCCGCATGTGTCTGTATTCATACAGCACTACTTACTTAGAGATGCTACTGTCAGTGTCCTCAGGGCTCTACCAAGACATAATGCACTGGGGTACCACATGGTCCATTTCATGTGATCTATTACTCTGACATAAACCCATCTGTAATATATTGCCAGTATATAAGCTGTTTAGTTTGTTAATTGATTAAACTGTATGTCTTATAAGAAAACATGTAAAGGGGGAATATATGGGGGGAGTGAGCTCTCTCAGACCCTTGAAGATGTAGCTTCCAAATTTGAATGGATTAAATGGCACCTGTATACCAATTTGTAGAAAGAACATATGTGATACTTATGTAAAGTGTGGGGCGAGTGGGTAACAGTTTTCAGGCACAAAATGGTTTGGCCTTCTGAAGGCAGGTGTGAATAAAAGCTGAGAGTCTTTTCTGTGACAGTAAAGAGTAGGAGAGACTGGAGGGTAGTGTGTGGTGTGGACTAAGACTGAAAGGAGGTTATTACCCAGATACTAGGAGACACTGGTGTCCCTGTTTTAGAGATTTGGCTCTATACCCATTTGTCATTTCTCAATTACTGGTCACAACAAGAGGCCACTGGAGAAAGTGGCAGGTGGTGAAGCAAGGTTATTGTGTGTGCTTTTGATGATAAGAATCTCTCTCTGGAACTGAGCAGAATTGCCTCCATGTGAATTCCTTCAACAAAAAAATGAGCCTGCCTAGACTACTTTCAGATTGTGGATTGTGTTTTCCATGTGTGGGCTGCTTCCCTGATTCATACTCTGCCAAAGTTTTATTTTGAGAAATAATATTACTTTCCTCTTCTGAAATAAAATAATAATAATAATAATGAAACCCCCAAACCACAGTGTGAGTCTCAGGTTAGCATTTGAAAACATCTCCAGAGACATTGTTATTCCTCAGGAGTTTCCCTGACTCCTTAATGTGGCTGATGTTTCATGTTTATTTATTTATTTTAATAAGTATGAGCAATCGAAGGGCTGATCATCTGAGTTTTGTACTGCAGTAGATGTAAGAGCAATAACTCTGCCCATAAATTTACTGCTGCCAAATAGTTTTAGCAATATGAGTTTGTCTTAAAAGCCATGAAGCATTAATGTCAATGTTTAGCAAAATCTCCAGAATTTAGCTTAAATTAAATTAAATGAAAGTGCTTTCCTGAGCACTTAAGGAGGCACTGTGAAACATCTTGGTTATGTACAAGGCAATACCAAGGTGATCTCAGCAATAATCAGGCTTCCCTTCTTATTCACTTCGAAGTATCCATCACAGTTATTTGCACTCTGACCATGTTGGTGCTCACTAGAGTGGTGATATTTCACCTGAAGAAGTGAAAGACAGGAAGTGGATGGTTGATGAGTGTGAACTGATTGGCAAATAGAATATCCCCAAAACAGAGCAAACAAGAATGCCAGTGCTCTGAAAACTGCCTTAAATATAATAATAGGGAACTTTCTTTCTCTCTTCAAGCAATAGAGACCACAGGGAACTGCACCCACCTGCACCATCGCCATGCCAGTGGTGCTGCCATTCTGAGATTATTTCACACAGTCAGATTCAGTACACGCAGTCATTTGTTTAAAATAAATAGAAGAACATTCCTTTGTGCAGCTTGTCCCCTGGAATAAAAATGGCCCATTTTCTCTA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Testis </TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Nervous system</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Mitochondrion</CellLocal>
      <Ontology_ID>GO:0005739</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MAPK10</Gene_Name>
    <Gene_Alias>JNK3; JNK3A; PRKM10; SAPK1B</Gene_Alias>
    <Gene_ID>5602</Gene_ID>
    <Genbank_ACCN>NM_002753</Genbank_ACCN>
    <Protein_ACCN>NP_002744</Protein_ACCN>
    <HGNC_ID>6872</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5602</Gene_URL>
    <UCSC_ID>uc003hpt.3</UCSC_ID>
    <EMBL_ID>ENSG00000109339</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q04206</Uniprot_ID>
      <Gene_Name>RELA</Gene_Name>
      <EBI_ID>EBI-73886</EBI_ID>
      <PPI_EBI_URL>EBI-713543,EBI-73886</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Coffin-Lowry Syndrome</Disease_Name>
      <Disease_Detail>Coffin-Lowry Syndrome</Disease_Detail>
      <Disease_DB>CFF002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coffin_lowry_syndrome?search=MAPK10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lennox-Gastaut Syndrome</Disease_Name>
      <Disease_Detail>Lennox-Gastaut Syndrome</Disease_Detail>
      <Disease_DB>LNN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lennox_gastaut_syndrome?search=MAPK10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Insensitivity to Pain with Anhidrosis</Disease_Name>
      <Disease_Detail>Congenital Insensitivity to Pain with Anhidrosis</Disease_Detail>
      <Disease_DB>CNG402</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_insensitivity_to_pain_with_anhidrosis?search=MAPK10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Opioid Abuse</Disease_Name>
      <Disease_Detail>Opioid Abuse</Disease_Detail>
      <Disease_DB>OPD001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/opioid_abuse?search=MAPK10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anhidrosis</Disease_Name>
      <Disease_Detail>Anhidrosis</Disease_Detail>
      <Disease_DB>ANH002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anhidrosis?search=MAPK10#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor</PDB_Title>
      <PDB_ID>2ZDU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZDU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1)</PubMed_Title>
      <Author>Asano, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2008)16:4715-4732</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18313304?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding</PDB_Title>
      <PDB_ID>3CGF</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CGF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding</PubMed_Title>
      <Author>Buckley, G.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:3291-3295</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18482836?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>JNK3 bound to aminopyrimidine inhibitor, SR-3562</PDB_Title>
      <PDB_ID>3KVX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KVX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors</PubMed_Title>
      <Author>Kamenecka, T., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:419-431</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19947601?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of JNK3 in Complex with SAB Peptide</PDB_Title>
      <PDB_ID>4H3B</PDB_ID>
      <Resolution>2.08</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4H3B</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10090003</ASD_Ligand>
      <PubMed_Title>Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases.</PubMed_Title>
      <Author>Laughlin, J.D., et al.</Author>
      <Journal>Structure(2012)20:2174-2184</Journal>
      <PubMed_ID>23142346</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin-2-one</PDB_Title>
      <PDB_ID>3G9L</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G9L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.</PubMed_Title>
      <Author>Cao, J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2891-2895</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19361991?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide</PDB_Title>
      <PDB_ID>2O2U</PDB_ID>
      <Resolution>2.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2O2U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.</PubMed_Title>
      <Author>Angell, R.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:1296-1301</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17194588?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of JNK3 in complex with a phenantroline inhibitor</PDB_Title>
      <PDB_ID>1PMU</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PMU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity</PubMed_Title>
      <Author>Scapin, G., et al.</Author>
      <Journal>Chem.Biol.(2003)10:705-712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12954329?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor</PDB_Title>
      <PDB_ID>1PMN</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity</PubMed_Title>
      <Author>Scapin, G., et al.</Author>
      <Journal>Chem.Biol.(2003)10:705-712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12954329?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding</PDB_Title>
      <PDB_ID>3CGO</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CGO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding</PubMed_Title>
      <Author>Buckley, G.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:3291-3295</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18482836?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of potent and selective covalent inhibitors of JNK</PDB_Title>
      <PDB_ID>3V6S</PDB_ID>
      <Resolution>2.97</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V6S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of potent and selective covalent inhibitors of JNK.</PubMed_Title>
      <Author>Zhang, T., et al.</Author>
      <Journal>Chem.Biol.(2012)19:140-154</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22284361?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-reperfusion injury</PDB_Title>
      <PDB_ID>3TTJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TTJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.</PubMed_Title>
      <Author>Krenitsky, V.P., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:1427-1432</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22226655?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of JNK3 in complex with an imidazole-pyrimidine inhibitor</PDB_Title>
      <PDB_ID>1PMQ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PMQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity</PubMed_Title>
      <Author>Scapin, G., et al.</Author>
      <Journal>Chem.Biol.(2003)10:705-712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12954329?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitors</PDB_Title>
      <PDB_ID>2P33</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P33</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors</PubMed_Title>
      <Author>Alam, M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:3463-3467</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17459703?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of JNK3 in Complex with ATF2 Peptide</PDB_Title>
      <PDB_ID>4H36</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4H36</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10090001</ASD_Ligand>
      <PubMed_Title>Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases.</PubMed_Title>
      <Author>Laughlin, J.D., et al.</Author>
      <Journal>Structure(2012)20:2174-2184</Journal>
      <PubMed_ID>23142346</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of potent and selective covalent inhibitors of JNK</PDB_Title>
      <PDB_ID>3V6R</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V6R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of potent and selective covalent inhibitors of JNK.</PubMed_Title>
      <Author>Zhang, T., et al.</Author>
      <Journal>Chem.Biol.(2012)19:140-154</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22284361?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of JNK3 in Complex with JIP1 Peptide</PDB_Title>
      <PDB_ID>4H39</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4H39</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10090002</ASD_Ligand>
      <PubMed_Title>Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases.</PubMed_Title>
      <Author>Laughlin, J.D., et al.</Author>
      <Journal>Structure(2012)20:2174-2184</Journal>
      <PubMed_ID>23142346</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-3,4-DIHYDROISOQUINOLINE INHIBITOR</PDB_Title>
      <PDB_ID>2WAJ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WAJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>1-Aryl-3,4-Dihydroisoquinoline Inhibitors of Jnk3.</PubMed_Title>
      <Author>Christopher, J.A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2230</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19303774?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP</PDB_Title>
      <PDB_ID>1JNK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JNK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.</PubMed_Title>
      <Author>Xie, X., et al.</Author>
      <Journal>Structure(1998)6:983-991</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9739089?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacokinetic Properties</PDB_Title>
      <PDB_ID>3OY1</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OY1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.</PubMed_Title>
      <Author>Probst, G.D., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:315-319</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21112785?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor</PDB_Title>
      <PDB_ID>1PMV</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PMV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity</PubMed_Title>
      <Author>Scapin, G., et al.</Author>
      <Journal>Chem.Biol.(2003)10:705-712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12954329?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin-2-one</PDB_Title>
      <PDB_ID>3G9N</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G9N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.</PubMed_Title>
      <Author>Cao, J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2891-2895</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19361991?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor</PDB_Title>
      <PDB_ID>3TTI</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TTI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.</PubMed_Title>
      <Author>Plantevin Krenitsky, V., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:1433-1438</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22244937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451</PDB_Title>
      <PDB_ID>3FI2</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FI2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.</PubMed_Title>
      <Author>Kamenecka, T., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:12853-12861</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19261605?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide</PDB_Title>
      <PDB_ID>2O0U</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2O0U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.</PubMed_Title>
      <Author>Angell, R.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:1296-1301</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17194588?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor</PDB_Title>
      <PDB_ID>2ZDT</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (2)</PubMed_Title>
      <Author>Asano, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2008)16:4699-4714</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18313930?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1H-benzo[d]imidazol-2-amine</PDB_Title>
      <PDB_ID>3DA6</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DA6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase</PubMed_Title>
      <Author>Cee, V.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:424-427</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19062275?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide</PDB_Title>
      <PDB_ID>2OK1</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OK1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors.</PubMed_Title>
      <Author>Aronov, A.M., et al.</Author>
      <Journal>J.Med.Chem.(2007)50:1280-1287</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17300186?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor</PDB_Title>
      <PDB_ID>3PTG</PDB_ID>
      <Resolution>2.43</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PTG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor.</PubMed_Title>
      <Author>Bowers, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1838-1843</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21316234?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of JNK3 with indazole inhibitor, SR-3737</PDB_Title>
      <PDB_ID>3FI3</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FI3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.</PubMed_Title>
      <Author>Kamenecka, T., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:12853-12861</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19261605?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatment of Neurodegenerative Diseases</PDB_Title>
      <PDB_ID>3OXI</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OXI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.</PubMed_Title>
      <Author>Hom, R.K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:7303-7307</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21071223?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Inhibitor complex of JNK3</PDB_Title>
      <PDB_ID>2EXC</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2EXC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Inhibitor complex of JNK3</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>JNK3 bound to piperazine amide inhibitor, SR2774.</PDB_Title>
      <PDB_ID>3FV8</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FV8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.</PubMed_Title>
      <Author>Shin, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:3344-3347</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19433357?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indolin-2-one</PDB_Title>
      <PDB_ID>3G90</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G90</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.</PubMed_Title>
      <Author>Cao, J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2891-2895</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19361991?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor</PDB_Title>
      <PDB_ID>2R9S</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R9S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.</PubMed_Title>
      <Author>Jiang, R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:6378-6382</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17911023?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>inhibitor complex of JNK3</PDB_Title>
      <PDB_ID>2B1P</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B1P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3</PubMed_Title>
      <Author>Swahn, B.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:5095-5099</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16140012?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.ba.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta </CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1jnk</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Laughlin JD, et al. Structure. 2012 Nov 6. pii: S0969-2126(12)00374-7. doi: 10.1016/j.str.2012.09.021.</Site_Reference>
      <Site_Type>Autoinhibited-activated switch model</Site_Type>
      <PubMed_ID>23142346</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.24</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/24.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD10090001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10090002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10090003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2013-04-23</Create_Date>
</Organism_Record>